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Abstract. Background: The staging can be used as one of the prognostic factors providing 
a clinical picture of the patient in the future in colorectal cancer patient. In addition, 
carcinoembryonic antigen (CEA) as tumor markers can determine the commonly used 
diagnosis and prognosis of colorectal cancer. Objective: The aims study was to investigate 
the relationship of the staging and carcinoembryonic antigen serum levels in colorectal cancer 
patients. Methods. This was an analytical study with a cross-sectional design. The sample 
used was colorectal cancer patients at H. Adam Malik General Hospital, Medan from January 
2016 to December 2018. As many as 52 subject study who met the inclusion and exclusion 
criteria. The Kruskal-Wallis test was used to determine relationship between staging and 
CEA serum levels. Results: The median value of carcinoembryonic antigen levels in Stage 
I, II, III, and IV group was (2.74 ng/ml vs 6.16 ng/ml vs 2.52 ng/ml, vs 26.87 ng/ml; p=0.003) 
respectively. Conclusion: There was relationship between staging and carcinoembryonic 
antigen serum levels in colorectal cancer patient.    
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Abstrak. Pendahuluan: Stadium dapat digunakan sebagai salah satu faktor prognostik 
yang memberikan gambaran klinis pasien di masa depan pada pasien kanker kolorektal. Di 
samping itu, kadar Antigen Carcinoembryonic (CEA) sebagai penanda tumor, dapat 
menentukan diagnosis dan prognosis kanker kolorektal yang umum digunakan. Tujuan: 
Penelitian ini bertujuan untuk menyelidiki hubungan antara stadium dengan kadar CEA 
pada pasien kanker kolorektal. Metode: Penelitian ini merupakan penelitian analitik dengan 
desain potong lintang. Sampel yang digunakan adalah pasien kanker kolorektal di Rumah 
Sakit Umum H. Adam Malik, Medan periode Januari 2016-Desember 2018. Sebanyak 52 
subjek penelitian yang memenuhi kriteria inklusi dan eksklusi. Tes Kruskal-Wallis digunakan 
untuk menentukan hubungan antara stadium dan kadar serum CEA. Hasil: Nilai median 
kadar serum CEA pada stadium I, II, III, dan IV adalah masing-masing (2.74 ng / ml vs 6.16 
ng / ml vs 2.52 ng / ml, vs 26.87 ng / ml ; p = 0.003). Kesimpulan: Terdapat hubungan antara 
stadium dan kadar serum CEA pada pasien kanker kolorektal.  
Kata Kunci: Kanker kolorektal, Carcioembryonic Antigen, Stadium tumor 
Received 10 May 2020 | Revised 25 August 2020 | Accepted 28 August 2020 
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) Vol. 02, No. 3, 2020                        119                                                          
 
1 Introduction 
Colorectal cancer is a malignant condition arising from abnormal growth of tissue cells 
originating from the large intestine and/or rectum.[1] Increasing mortality (880 thousand) in  the 
general population has caused colorectal cancer as the second leading cause of cancer deaths 
worldwide.[2] In Indonesia, the incidence of colorectal cancer was ranked fourth with an 
incidence rate of 12.1 per 100,000 and rank fifth as the cause of death after breast, cervical, lung, 
and liver cancer. The mortality rate caused by colorectal cancer reaches 6.9 per 100,000 of all 
cancers.[3] Many factors that contribute to colorectal cancer such as sex, age, race, obesity, 
alcohol consumption, and red meat, and smoking are risk factors for colorectal cancer. [4] 
American Joint Committee for Cancer Executives (AJCC) classified colorectal cancer into four 
stages namely Stage I, II (A, B, and C), III (A, B, and C), IV (A and B).[5] The higher the number 
of stages suffered, the smaller of survival rate. [6] Early detection in the early stages of colorectal 
cancer becomes very important cause can be a prognostic factor in determining survival rate of 
colorectal cancer patients. This is what underlies the need for screening test.  
Carcinoembryonic antigen (CEA) serum is the most commonly used biomarker in laboratory tests 
for screening, diagnosis, prognostication, and monitoring of treatment and recurrence in  patients 
with colorectal cancer. Seventy-two point four percent (72.4%) of colorectal cancer  patients have 
elevated levels of CEA. [7–9]. In Medan, there is still no previous studies on the relationship 
between staging and CEA levels in a patient with colorectal cancer. Therefore, the author would 
like to research the relationship between staging and CEA levels in colorectal cancer patients 
suffers in H. Adam Malik General Hospital, Medan. 
2 Methods 
This was an analytical study with cross-sectional design. The study was carried out at H. Adam 
Malik General Hospital, Medan. The study subjects were patients who were diagnosed with 
colorectal cancer colonoscopy and histopathology examinations from January 2016-December 
2018.  
The inclusion criteria in this study were patients diagnosed with colorectal cancer, there are 
laboratory data for examination of CEA and tumor stages. Meanwhile, the exclusion criteria 
include incomplete data and patients suffering from other comorbid diseases such as hepatitis and 
hyperthyroidism. The following data were collected from medical records: age, gender, CEA 
level, tumor location, and staging. 
Statistical analysis was performed using SPSS version 22.0, with 95 % confident interval. To 
examine relationship between staging and CEA serum levels was tested by Kruskal-Wallis test 
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and followed by the Mann-Whitney test to determine the difference between carcinoembryonic 
antigen serum levels in various staging groups. 
3 Results 
Based on the inclusion and exclusion criteria obtained 52 of 71 patient’s data that becomes the 
sample of study. The characteristic of the colorectal cancer patients, gender, age, site of cancer, 
and staging, are presented in Table 1. Table 2 presents the Kruskal-Wallis test. The test showed 
that a significant result (p = 0.003) was obtained between the staging with CEA levels. The post 
hoc test was used to determinate which group has a difference. Stage I and IV, II and IV, III and 
IV showed that significant results, p=0.001, 0.017, 0.021 respectively. Meanwhile, the others 
group was statistically not significant (table 3)  
Table 1 The Characterictics of Subjects (n=52) 
Variable n (%) 
Age (years)  
≥ 50  33 (63.5 %) 
< 50  19 (36.5%) 
Gender  
Male (28) 5.8 % 
Female (24) 46.2 % 
Site of cancer  
Right-sided 5 (9.6 %) 
Left-sided 21 (40.4%) 
Rectum 26 (50%) 
Stage  
    I 24 (46.2 %) 
II 9 (17.3 %) 
III 4 (7.7%) 
IV 15 (28.8%) 
 
Table 2 Relationship Between Staging and CEA Serum Levels 
Variable 
















26.87 (4.2-1759) 0.003 
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Table 3 Comparison of CEA Serum Levels Among The Colorectal Cancer Stages 
Staging Groups CEA level (ng/ml)* P ** 
I vs II 2.74 (1.04 -1968.9) vs 6.16 (0.98 – 1500)  0.352 
I vs III 2.74 (1.04 -1968.9) vs 2.52 (1.8-22.2) 0.896 
I vs IV 2.74 (1.04 -1968.9) vs 26.87 (4.2-1759)  0.001 
II vs III 6.16 (0.98 – 1500) vs 2.52 (1.8-22.2) 0.537 
II vs IV 6.16 (0.98 – 1500) vs 26.87 (4.2-1759)  0.017 
III vs IV 2.52 (1.8-22.2) vs 26.87 (4.2-1759)  0.021 
*Values are median(minimun-maximum); **Mann-Whitney test 
4 Discussion 
CEA is a cancer tumor marker and is predominantly used clinically in conditions with colorectal 
cancer. It is an oncofetal protein that is normally present during fetal life but may be present in 
healthy adults in low concentrations.[10] 
Among the 52 subjects, patients with colorectal cancer were dominated by male (53,8 %) than 
female (46,2 %). The male gender has the risk of colorectal cancer occurrence than in female.It 
is suspected that this is due to the tendency of men to prefer diets that are high in red meat and its 
processed products as well as a higher alcohol consumption and smoking habit and a  greater 
chance of visceral fat accumulation associated with an increased risk of colorectal cancer.[11-12] 
The most frequent site of cancer in colorectal cancer patients was the rectum by 60% (26 cases), 
as compared with others site. Yusra et al [13] also obtained a similar result showing that the most 
common site of colorectal cancer was rectum by 55.9%. However, it is different from a research 
by Gunasekaran et al [14] stating that the most frequent site of colorectal cancer was colon by 
40.5%.  
Our study showed that increasing CEA levels serum with increasing stages of colorectal cancer 
and the relationship was statistically significant. Similar results were found by Barata[8], showing 
that the end of stage of colorectal cancer produced more higher CEA levels compare the others. 
This is in contrast of previous study, who stated that there was no statistically significant 
relationship between the CEA levels and staging of colorectal cancer patient’s.[15]  
The CEA levels may be within normal limits in the majority of patients with colorectal cancer. 
Increased CEA pre-operative learning outcomes associated with the bad prognosis post-surgery, 
Journal of Endocrinology, Tropical Medicine, and Infectiouse Disease (JETROMI) Vol. 02, No. 3, 2020                        122                                                          
 
besides of course the affected by staging and grading of tumor histopathology.[16] The 
mechanism of CEA in increasing the incidence of advanced stages in colorectal cancer is still not 
fully understood yet, but according to the previous study, CEA can activate Kupfer cells in the 
liver to induce the overexpression of cytokines and change the liver microenvironment to allow 
circulating colorectal tumor cells to survive in the liver.[17] 
5 Conclusion 
There was significant results between staging and CEA serum levels in colorectal cancer patients. 
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